» Articles » PMID: 39188984

Recent Advances of the Ephrin and Eph Family in Cardiovascular Development and Pathologies

Overview
Journal iScience
Publisher Cell Press
Date 2024 Aug 27
PMID 39188984
Authors
Affiliations
Soon will be listed here.
Abstract

Erythropoietin-producing hepatoma (Eph) receptors, comprising the largest family of receptor tyrosine kinases (RTKs), exert profound influence on diverse biological processes and pathological conditions such as cancer. Interacting with their corresponding ligands, erythropoietin-producing hepatoma receptor interacting proteins (Ephrins), Eph receptors regulate crucial events like embryonic development, tissue boundary formation, and tumor cell survival. In addition to their well-established roles in embryonic development and cancers, emerging evidence highlights the pivotal contribution of the Ephrin/Eph family to cardiovascular physiology and pathology. Studies have elucidated their involvement in cardiovascular development, atherosclerosis, postnatal angiogenesis, and, more recently, cardiac fibrosis and calcification, suggesting a promising avenue for therapeutic interventions in cardiovascular diseases. There remains a need for a comprehensive synthesis of their collective impact in the cardiovascular context. By exploring the intricate interactions between Eph receptors, ephrins, and cardiovascular system, this review aims to provide a holistic understanding of their roles and therapeutic potential in cardiovascular health and diseases.

Citing Articles

Simultaneous isolation and culture of endothelial colony-forming cells, endothelial cells and vascular smooth muscle cells from human umbilical cords.

Burger M, Menetrey S, Ponti C, Lepigeon K, Sichitiu J, Peyter A Mol Biol Rep. 2025; 52(1):302.

PMID: 40080230 PMC: 11906538. DOI: 10.1007/s11033-025-10418-1.


EphA2 in Cancer: Molecular Complexity and Therapeutic Opportunities.

Toracchio L, Carrabotta M, Mancarella C, Morrione A, Scotlandi K Int J Mol Sci. 2024; 25(22).

PMID: 39596256 PMC: 11594831. DOI: 10.3390/ijms252212191.

References
1.
Adams R, Diella F, Hennig S, Helmbacher F, Deutsch U, Klein R . The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration. Cell. 2001; 104(1):57-69. DOI: 10.1016/s0092-8674(01)00191-x. View

2.
Gale N, Holland S, Valenzuela D, Flenniken A, Pan L, Ryan T . Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron. 1996; 17(1):9-19. DOI: 10.1016/s0896-6273(00)80276-7. View

3.
Foubert P, Silvestre J, Souttou B, Barateau V, Martin C, Ebrahimian T . PSGL-1-mediated activation of EphB4 increases the proangiogenic potential of endothelial progenitor cells. J Clin Invest. 2007; 117(6):1527-37. PMC: 1866248. DOI: 10.1172/JCI28338. View

4.
Sesen J, Ghalali A, Driscoll J, Martinez T, Lupieri A, Zurakowski D . Discovery and Characterization of Ephrin B2 and EphB4 Dysregulation and Novel Mutations in Cerebral Cavernous Malformations: In Vitro and Patient-Derived Evidence of Ephrin-Mediated Endothelial Cell Pathophysiology. Cell Mol Neurobiol. 2023; 44(1):12. PMC: 11407144. DOI: 10.1007/s10571-023-01447-0. View

5.
Lin K, Sloniowski S, Ethell D, Ethell I . Ephrin-B2-induced cleavage of EphB2 receptor is mediated by matrix metalloproteinases to trigger cell repulsion. J Biol Chem. 2008; 283(43):28969-79. PMC: 2570862. DOI: 10.1074/jbc.M804401200. View